BioTech
-
Novo Nordisk defends Ozempic, Wegovy prices amid Senate probe
Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy amid a Senate probe into…
Read More » -
Novo Nordisk, Moderna, Novartis, raw milk
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Adam’s Biotech Scorecard: Novartis’ MorphoSys boondoggle
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it…
Read More » -
Novartis extends radiopharma plans with $1B acquisition of Mariana Oncology
Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even more attention to these cancer…
Read More » -
BridgeBio spins out cancer company to concentrate on heart drug
BridgeBio Pharma is spinning out its oncology subsidiary into a fully independent company, as it concentrates its resources on an…
Read More » -
Moderna breaks off deal with CRISPR company Metagenomi
Three years ago, Moderna, flush with cash from Covid vaccine sales, announced it would start investing in the burgeoning field…
Read More » -
Pfizer, Johnson & Johnson, Walmart, Ozempic
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Lilly, Bristol Meyers Squibb, Johnson & Johnson
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Eli Lilly raises earnings guidance as Zepbound sales beat expectations
Eli Lilly raised its full-year guidance on Tuesday while it reported strong first-quarter sales of Zepbound, even as the pharmaceutical…
Read More » -
Chinese Spy Agency Rising to Challenge the C.I.A.
The Chinese spies wanted more. In meetings during the pandemic with Chinese technology contractors, they complained that surveillance cameras tracking…
Read More »